Alnylam Pharmaceuticals (ALNY) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 20, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and annual reports before voting.

Voting matters and shareholder proposals

• Election of three Class I director nominees: Stuart A. Arbuckle, Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D.

• Advisory vote to approve compensation of named executive officers.

• Ratification of PricewaterhouseCoopers LLP as independent auditors for fiscal year ending December 31, 2026.

• Proxies may vote on other business that arises at the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.